Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study
Background We conducted exploratory analyses to identify distinct trajectories of estimated glomerular filtration rate (eGFR) and their relationship with hyperfiltration, subsequent rapid eGFR decline, and albuminuria in participants with youth-onset type 2 diabetes enrolled in the Treatment Options...
Gespeichert in:
| Veröffentlicht in: | Pediatric nephrology (Berlin, West) West), 2023-12, Vol.38 (12), p.4137-4144 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4144 |
|---|---|
| container_issue | 12 |
| container_start_page | 4137 |
| container_title | Pediatric nephrology (Berlin, West) |
| container_volume | 38 |
| creator | El ghormli, Laure Wen, Hui Uschner, Diane Haymond, Morey W. Hughan, Kara S. Kutney, Katherine Laffel, Lori Tollefsen, Sherida E. Escaname, Elia N. Lynch, Jane Bjornstad, Petter |
| description | Background
We conducted exploratory analyses to identify distinct trajectories of estimated glomerular filtration rate (eGFR) and their relationship with hyperfiltration, subsequent rapid eGFR decline, and albuminuria in participants with youth-onset type 2 diabetes enrolled in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study.
Methods
Annual serum creatinine, cystatin C, urine albumin, and creatinine measurements were obtained from 377 participants followed for ≥ 10 years. Albuminuria and eGFR were calculated. Hyperfiltration peak is the greatest eGFR inflection point during follow-up. Latent class modeling was applied to identify distinct eGFR trajectories.
Results
At baseline, participants’ mean age was 14 years, type 2 diabetes duration was 6 months, mean HbA1c was 6%, and mean eGFR was 120 ml/min/1.73 m
2
. Five eGFR trajectories associated with different rates of albuminuria were identified, including a “progressive increasing eGFR” group (10%), three “stable eGFR” groups with varying starting mean eGFR, and an “eGFR steady decline” group (1%). Participants who exhibited the greatest peak eGFR also had the highest levels of elevated albuminuria at year 10. This group membership was characterized by a greater proportion of female and Hispanic participants.
Conclusions
Distinct eGFR trajectories that associate with albuminuria risk were identified, with the eGFR trajectory characterized by increasing eGFR over time associating with the highest level of albuminuria. These descriptive data support the current recommendations to estimate GFR annually in young persons with type 2 diabetes and provide insight into eGFR-related factors which may contribute to predictive risk strategies for kidney disease therapies in youth with type 2 diabetes.
Trial registration
ClinicalTrials.gov Identifier: NCT00081328, date registered 2002.
Graphical abstract
A higher resolution version of the Graphical abstract is available as
Supplementary information |
| doi_str_mv | 10.1007/s00467-023-06044-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2836292254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A769513840</galeid><sourcerecordid>A769513840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-6e5772e1953d0772e7e2ddcaa87d7c3688224c41181c60065c913e5af81b5e173</originalsourceid><addsrcrecordid>eNp9kl9rFDEUxQdR7Fr9Aj5IQBBfpubvJOPbUm0VCgVZoT6FbObObtaZZJtkkP32Zt1qrSwSuAn3_s4hXE5VvST4jGAs3yWMeSNrTFmNG8x5zR5VM8IZrUmrbh5XM9wyUmNObk6qZyltMMZKqOZpdcIkZxxTOavCIpoN2Byig4RCj-Dy4gsyvkPRpe_7hhmW0-j8FJ1BzqNdmPIa_XCl5N0WEEWdM0vIkN6jCGkackJ9DCPKa0CL6w_zb8iGdYgZpTx1u-fVk94MCV7c3afV14uPi_NP9dX15efz-VVtBSG5bkBISYG0gnV4_5JAu84ao2QnLWuUopRbTogitsG4EbYlDITpFVkKIJKdVm8PvtsYbidIWY8uWRgG4yFMSVPFGtpSKnhBX_-DbsIUffldoaQSgjHc3FMrM4B2vg85Grs31XPZtIIwxXGh6iPUCjxEMwQPvSvtB_zZEb6cDkZnjwre_CVYgxnyOoVhyi749BCkB9DGkFKEXm-jG03caYL1Pj76EB9d4qN_xUezInp1t4ppOUL3R_I7LwVgByCVkV9BvN_Vf2x_AqPwy5I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2878553306</pqid></control><display><type>article</type><title>Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>El ghormli, Laure ; Wen, Hui ; Uschner, Diane ; Haymond, Morey W. ; Hughan, Kara S. ; Kutney, Katherine ; Laffel, Lori ; Tollefsen, Sherida E. ; Escaname, Elia N. ; Lynch, Jane ; Bjornstad, Petter</creator><creatorcontrib>El ghormli, Laure ; Wen, Hui ; Uschner, Diane ; Haymond, Morey W. ; Hughan, Kara S. ; Kutney, Katherine ; Laffel, Lori ; Tollefsen, Sherida E. ; Escaname, Elia N. ; Lynch, Jane ; Bjornstad, Petter ; TODAY Study Group ; for the TODAY Study Group</creatorcontrib><description>Background
We conducted exploratory analyses to identify distinct trajectories of estimated glomerular filtration rate (eGFR) and their relationship with hyperfiltration, subsequent rapid eGFR decline, and albuminuria in participants with youth-onset type 2 diabetes enrolled in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study.
Methods
Annual serum creatinine, cystatin C, urine albumin, and creatinine measurements were obtained from 377 participants followed for ≥ 10 years. Albuminuria and eGFR were calculated. Hyperfiltration peak is the greatest eGFR inflection point during follow-up. Latent class modeling was applied to identify distinct eGFR trajectories.
Results
At baseline, participants’ mean age was 14 years, type 2 diabetes duration was 6 months, mean HbA1c was 6%, and mean eGFR was 120 ml/min/1.73 m
2
. Five eGFR trajectories associated with different rates of albuminuria were identified, including a “progressive increasing eGFR” group (10%), three “stable eGFR” groups with varying starting mean eGFR, and an “eGFR steady decline” group (1%). Participants who exhibited the greatest peak eGFR also had the highest levels of elevated albuminuria at year 10. This group membership was characterized by a greater proportion of female and Hispanic participants.
Conclusions
Distinct eGFR trajectories that associate with albuminuria risk were identified, with the eGFR trajectory characterized by increasing eGFR over time associating with the highest level of albuminuria. These descriptive data support the current recommendations to estimate GFR annually in young persons with type 2 diabetes and provide insight into eGFR-related factors which may contribute to predictive risk strategies for kidney disease therapies in youth with type 2 diabetes.
Trial registration
ClinicalTrials.gov Identifier: NCT00081328, date registered 2002.
Graphical abstract
A higher resolution version of the Graphical abstract is available as
Supplementary information</description><identifier>ISSN: 0931-041X</identifier><identifier>ISSN: 1432-198X</identifier><identifier>EISSN: 1432-198X</identifier><identifier>DOI: 10.1007/s00467-023-06044-3</identifier><identifier>PMID: 37434027</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Albuminuria ; Albuminuria - complications ; Albuminuria - etiology ; Children & youth ; Cohort analysis ; Cohort Studies ; Complications and side effects ; Creatinine ; Cystatin C ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetic Nephropathies - diagnosis ; Diabetic Nephropathies - epidemiology ; Diabetic Nephropathies - etiology ; Disease Progression ; Epidermal growth factor receptors ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Health aspects ; Health risks ; Humans ; Kidney diseases ; Medicine ; Medicine & Public Health ; Nephrology ; Original Article ; Pediatric research ; Pediatrics ; Risk Factors ; Type 2 diabetes ; Urology</subject><ispartof>Pediatric nephrology (Berlin, West), 2023-12, Vol.38 (12), p.4137-4144</ispartof><rights>The Author(s), under exclusive licence to International Pediatric Nephrology Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.</rights><rights>COPYRIGHT 2023 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-6e5772e1953d0772e7e2ddcaa87d7c3688224c41181c60065c913e5af81b5e173</citedby><cites>FETCH-LOGICAL-c511t-6e5772e1953d0772e7e2ddcaa87d7c3688224c41181c60065c913e5af81b5e173</cites><orcidid>0000-0003-4223-8407</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00467-023-06044-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00467-023-06044-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37434027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El ghormli, Laure</creatorcontrib><creatorcontrib>Wen, Hui</creatorcontrib><creatorcontrib>Uschner, Diane</creatorcontrib><creatorcontrib>Haymond, Morey W.</creatorcontrib><creatorcontrib>Hughan, Kara S.</creatorcontrib><creatorcontrib>Kutney, Katherine</creatorcontrib><creatorcontrib>Laffel, Lori</creatorcontrib><creatorcontrib>Tollefsen, Sherida E.</creatorcontrib><creatorcontrib>Escaname, Elia N.</creatorcontrib><creatorcontrib>Lynch, Jane</creatorcontrib><creatorcontrib>Bjornstad, Petter</creatorcontrib><creatorcontrib>TODAY Study Group</creatorcontrib><creatorcontrib>for the TODAY Study Group</creatorcontrib><title>Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study</title><title>Pediatric nephrology (Berlin, West)</title><addtitle>Pediatr Nephrol</addtitle><addtitle>Pediatr Nephrol</addtitle><description>Background
We conducted exploratory analyses to identify distinct trajectories of estimated glomerular filtration rate (eGFR) and their relationship with hyperfiltration, subsequent rapid eGFR decline, and albuminuria in participants with youth-onset type 2 diabetes enrolled in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study.
Methods
Annual serum creatinine, cystatin C, urine albumin, and creatinine measurements were obtained from 377 participants followed for ≥ 10 years. Albuminuria and eGFR were calculated. Hyperfiltration peak is the greatest eGFR inflection point during follow-up. Latent class modeling was applied to identify distinct eGFR trajectories.
Results
At baseline, participants’ mean age was 14 years, type 2 diabetes duration was 6 months, mean HbA1c was 6%, and mean eGFR was 120 ml/min/1.73 m
2
. Five eGFR trajectories associated with different rates of albuminuria were identified, including a “progressive increasing eGFR” group (10%), three “stable eGFR” groups with varying starting mean eGFR, and an “eGFR steady decline” group (1%). Participants who exhibited the greatest peak eGFR also had the highest levels of elevated albuminuria at year 10. This group membership was characterized by a greater proportion of female and Hispanic participants.
Conclusions
Distinct eGFR trajectories that associate with albuminuria risk were identified, with the eGFR trajectory characterized by increasing eGFR over time associating with the highest level of albuminuria. These descriptive data support the current recommendations to estimate GFR annually in young persons with type 2 diabetes and provide insight into eGFR-related factors which may contribute to predictive risk strategies for kidney disease therapies in youth with type 2 diabetes.
Trial registration
ClinicalTrials.gov Identifier: NCT00081328, date registered 2002.
Graphical abstract
A higher resolution version of the Graphical abstract is available as
Supplementary information</description><subject>Adolescent</subject><subject>Albuminuria</subject><subject>Albuminuria - complications</subject><subject>Albuminuria - etiology</subject><subject>Children & youth</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Complications and side effects</subject><subject>Creatinine</subject><subject>Cystatin C</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetic Nephropathies - diagnosis</subject><subject>Diabetic Nephropathies - epidemiology</subject><subject>Diabetic Nephropathies - etiology</subject><subject>Disease Progression</subject><subject>Epidermal growth factor receptors</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glomerular Filtration Rate</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Pediatric research</subject><subject>Pediatrics</subject><subject>Risk Factors</subject><subject>Type 2 diabetes</subject><subject>Urology</subject><issn>0931-041X</issn><issn>1432-198X</issn><issn>1432-198X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kl9rFDEUxQdR7Fr9Aj5IQBBfpubvJOPbUm0VCgVZoT6FbObObtaZZJtkkP32Zt1qrSwSuAn3_s4hXE5VvST4jGAs3yWMeSNrTFmNG8x5zR5VM8IZrUmrbh5XM9wyUmNObk6qZyltMMZKqOZpdcIkZxxTOavCIpoN2Byig4RCj-Dy4gsyvkPRpe_7hhmW0-j8FJ1BzqNdmPIa_XCl5N0WEEWdM0vIkN6jCGkackJ9DCPKa0CL6w_zb8iGdYgZpTx1u-fVk94MCV7c3afV14uPi_NP9dX15efz-VVtBSG5bkBISYG0gnV4_5JAu84ao2QnLWuUopRbTogitsG4EbYlDITpFVkKIJKdVm8PvtsYbidIWY8uWRgG4yFMSVPFGtpSKnhBX_-DbsIUffldoaQSgjHc3FMrM4B2vg85Grs31XPZtIIwxXGh6iPUCjxEMwQPvSvtB_zZEb6cDkZnjwre_CVYgxnyOoVhyi749BCkB9DGkFKEXm-jG03caYL1Pj76EB9d4qN_xUezInp1t4ppOUL3R_I7LwVgByCVkV9BvN_Vf2x_AqPwy5I</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>El ghormli, Laure</creator><creator>Wen, Hui</creator><creator>Uschner, Diane</creator><creator>Haymond, Morey W.</creator><creator>Hughan, Kara S.</creator><creator>Kutney, Katherine</creator><creator>Laffel, Lori</creator><creator>Tollefsen, Sherida E.</creator><creator>Escaname, Elia N.</creator><creator>Lynch, Jane</creator><creator>Bjornstad, Petter</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4223-8407</orcidid></search><sort><creationdate>20231201</creationdate><title>Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study</title><author>El ghormli, Laure ; Wen, Hui ; Uschner, Diane ; Haymond, Morey W. ; Hughan, Kara S. ; Kutney, Katherine ; Laffel, Lori ; Tollefsen, Sherida E. ; Escaname, Elia N. ; Lynch, Jane ; Bjornstad, Petter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-6e5772e1953d0772e7e2ddcaa87d7c3688224c41181c60065c913e5af81b5e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescent</topic><topic>Albuminuria</topic><topic>Albuminuria - complications</topic><topic>Albuminuria - etiology</topic><topic>Children & youth</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Complications and side effects</topic><topic>Creatinine</topic><topic>Cystatin C</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetic Nephropathies - diagnosis</topic><topic>Diabetic Nephropathies - epidemiology</topic><topic>Diabetic Nephropathies - etiology</topic><topic>Disease Progression</topic><topic>Epidermal growth factor receptors</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glomerular Filtration Rate</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Pediatric research</topic><topic>Pediatrics</topic><topic>Risk Factors</topic><topic>Type 2 diabetes</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El ghormli, Laure</creatorcontrib><creatorcontrib>Wen, Hui</creatorcontrib><creatorcontrib>Uschner, Diane</creatorcontrib><creatorcontrib>Haymond, Morey W.</creatorcontrib><creatorcontrib>Hughan, Kara S.</creatorcontrib><creatorcontrib>Kutney, Katherine</creatorcontrib><creatorcontrib>Laffel, Lori</creatorcontrib><creatorcontrib>Tollefsen, Sherida E.</creatorcontrib><creatorcontrib>Escaname, Elia N.</creatorcontrib><creatorcontrib>Lynch, Jane</creatorcontrib><creatorcontrib>Bjornstad, Petter</creatorcontrib><creatorcontrib>TODAY Study Group</creatorcontrib><creatorcontrib>for the TODAY Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric nephrology (Berlin, West)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El ghormli, Laure</au><au>Wen, Hui</au><au>Uschner, Diane</au><au>Haymond, Morey W.</au><au>Hughan, Kara S.</au><au>Kutney, Katherine</au><au>Laffel, Lori</au><au>Tollefsen, Sherida E.</au><au>Escaname, Elia N.</au><au>Lynch, Jane</au><au>Bjornstad, Petter</au><aucorp>TODAY Study Group</aucorp><aucorp>for the TODAY Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study</atitle><jtitle>Pediatric nephrology (Berlin, West)</jtitle><stitle>Pediatr Nephrol</stitle><addtitle>Pediatr Nephrol</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>38</volume><issue>12</issue><spage>4137</spage><epage>4144</epage><pages>4137-4144</pages><issn>0931-041X</issn><issn>1432-198X</issn><eissn>1432-198X</eissn><abstract>Background
We conducted exploratory analyses to identify distinct trajectories of estimated glomerular filtration rate (eGFR) and their relationship with hyperfiltration, subsequent rapid eGFR decline, and albuminuria in participants with youth-onset type 2 diabetes enrolled in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study.
Methods
Annual serum creatinine, cystatin C, urine albumin, and creatinine measurements were obtained from 377 participants followed for ≥ 10 years. Albuminuria and eGFR were calculated. Hyperfiltration peak is the greatest eGFR inflection point during follow-up. Latent class modeling was applied to identify distinct eGFR trajectories.
Results
At baseline, participants’ mean age was 14 years, type 2 diabetes duration was 6 months, mean HbA1c was 6%, and mean eGFR was 120 ml/min/1.73 m
2
. Five eGFR trajectories associated with different rates of albuminuria were identified, including a “progressive increasing eGFR” group (10%), three “stable eGFR” groups with varying starting mean eGFR, and an “eGFR steady decline” group (1%). Participants who exhibited the greatest peak eGFR also had the highest levels of elevated albuminuria at year 10. This group membership was characterized by a greater proportion of female and Hispanic participants.
Conclusions
Distinct eGFR trajectories that associate with albuminuria risk were identified, with the eGFR trajectory characterized by increasing eGFR over time associating with the highest level of albuminuria. These descriptive data support the current recommendations to estimate GFR annually in young persons with type 2 diabetes and provide insight into eGFR-related factors which may contribute to predictive risk strategies for kidney disease therapies in youth with type 2 diabetes.
Trial registration
ClinicalTrials.gov Identifier: NCT00081328, date registered 2002.
Graphical abstract
A higher resolution version of the Graphical abstract is available as
Supplementary information</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37434027</pmid><doi>10.1007/s00467-023-06044-3</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4223-8407</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-041X |
| ispartof | Pediatric nephrology (Berlin, West), 2023-12, Vol.38 (12), p.4137-4144 |
| issn | 0931-041X 1432-198X 1432-198X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2836292254 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adolescent Albuminuria Albuminuria - complications Albuminuria - etiology Children & youth Cohort analysis Cohort Studies Complications and side effects Creatinine Cystatin C Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetic Nephropathies - diagnosis Diabetic Nephropathies - epidemiology Diabetic Nephropathies - etiology Disease Progression Epidermal growth factor receptors Female Follow-Up Studies Glomerular Filtration Rate Health aspects Health risks Humans Kidney diseases Medicine Medicine & Public Health Nephrology Original Article Pediatric research Pediatrics Risk Factors Type 2 diabetes Urology |
| title | Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A42%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trajectories%20of%20eGFR%20and%20risk%20of%20albuminuria%20in%20youth%20with%20type%202%20diabetes:%20results%20from%20the%20TODAY%20cohort%20study&rft.jtitle=Pediatric%20nephrology%20(Berlin,%20West)&rft.au=El%20ghormli,%20Laure&rft.aucorp=TODAY%20Study%20Group&rft.date=2023-12-01&rft.volume=38&rft.issue=12&rft.spage=4137&rft.epage=4144&rft.pages=4137-4144&rft.issn=0931-041X&rft.eissn=1432-198X&rft_id=info:doi/10.1007/s00467-023-06044-3&rft_dat=%3Cgale_proqu%3EA769513840%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2878553306&rft_id=info:pmid/37434027&rft_galeid=A769513840&rfr_iscdi=true |